GW Pharmaceuticals progress with diabetes, epilepsy and schizophrenia cannabis medicines

Clinical trials to use cannabis in the treatment of debilitating illness proving successful for licensed UK company. Whilst the release of their flagship medicine, Sativex and its success in 24 countries around the world has been taking place, GW Pharmaceuticals have been developing more treatment options for illnesses that can…

Read Full Article

Big Pharma: Human Trials for Cannabis brain cancer treatment

On November the 11th 2013, GW Pharmaceuticals, (a UK pharmaceutical company currently operating under a government monopoly license to grow cannabis) announced that they will be conducting phase “1b/2a clinical trial” for the treatment of Gliobastoma Mulitiforme. Glioblastoma Mulitoforme is a rare, aggressive, malignant brain tumour that leaves patients a…

Read Full Article